**Abstract**

**Objective:** Sustained symptomatic remission in schizophrenia is considered to be associated with improved functional status. This post-hoc analysis of a 65 week (17 week open-label, 48 week double-blind \[DB\]), randomized, multicenter non-inferiority study examined symptomatic remission and functional recovery in acutely-ill Asian patients with schizophrenia receiving paliperidone palmitate 3-month (PP3M) or 1-month (PP1M) long-acting injectable.

**Methods**: Symptomatic remission (≤3 symptom score on P1, P2, P3, N1, N4, N6, G5, and G9 items of positive and negative symptom score for the last 6 months of 48-week DB treatment, on the basis of Andreason's criteria) and functional recovery (personal and social performance score\>70 for the last 6 months of DB treatment) were evaluated in Asian patients with schizophrenia from this global study (NCT01515423).

**Results**: At the end of DB treatment, 50% of patients receiving either PP3M (n=85) or PP1M (n=87) achieved sustained symptomatic remission (relative risk\>0.999, 95% CI: 0.82; 1.24). Baseline DB remitters from PP3M and PP1M groups continued to have better symptomatic remission status at DB endpoint (60 \[95.2%\] vs. 63 \[96.9%\]) than non-remitters (42 \[67.7%\] vs. 30 \[51.7%\]). The proportion of patients who remained stable (maintained remission with one excursion allowed) and had functional recovery in the last 6 months before study end was similar in both groups (PP3M: 49 \[28.8%\]; PP1M: 50 \[28.7%\]). Regardless of treatment type (PP3M or PP1M), baseline remitters showed higher remission rate and functional recovery (28 \[77.8%\] vs. 27 \[87.1%\]) at the end of DB treatment than non-remitters (33 \[37.1%\] vs. 25 \[27.2%\]).

**Conclusion**: Asian schizophrenia patients treated with either PP3M or PP1M injectable demonstrated a high rate of symptomatic remission across 48 weeks of DB treatment. The similar remission rates among study completers in both treatment groups, suggest better outcomes associated with long-acting treatments, resulting in sustained symptomatic and functional remission.
